4.6 Review

Safety of antidiabetes medications: An update

期刊

CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 98, 期 2, 页码 185-195

出版社

WILEY
DOI: 10.1002/cpt.125

关键词

-

资金

  1. AstraZeneca
  2. Bristol-Myers Squibb
  3. Amylin Pharmaceuticals

向作者/读者索取更多资源

Adverse iatrogenic effects of especial relevance for antidiabetes medications include hypoglycemic episodes, major adverse cardiovascular (CV) events, cancer, bone fractures, pancreatic effects, genital/urinary tract infections, and weight gain. Here, recent clinical studies addressing safety profiles of antidiabetes medications are reviewed. On balance, new prospective and population-based studies continue to indicate that the benefits of improved glucose control outweigh the risks associated with antidiabetes medications in most patients with type 2 diabetes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据